DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKindCorporation(Nasdaq:MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the first quarter of 2026, and provided a business update.

“We are making meaningful progress executing our corporate transformation strategy, focused on the expansion and diversification of both our commercial portfolio and development pipeline,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “2026 is the most catalyst-rich year in the Company’s history. The Furoscix ReadyFlow Autoinjector, if approved, represents an opportunity to scale the brand’s growth trajectory. At the same time, we are excited and prepared for the potential Afrezza approval and launch in pediatrics, which would address unmet needs of a new patient population. Combined with the continued momentum of Tyvaso DPI, including its expansion into IPF, a strengthening pipeline, and our expanded collaboration with United Therapeutics to advance ralinepag DPI, MannKind is well positioned to deliver sustained, long-term value for shareholders.”

Business Update and Upcoming Milestones 
Commercial Products   
Furoscix

Afrezza 

Development
Nintedanib DPI (MNKD-201) 

Ralinepag DPI (MNKD-1501)

Bumetanide DPI (MNKD-701)  

Corporate Update

First Quarter 2026 Financial Results

Revenues

    Three Months
Ended March 31, 		 
    2026     2025     $ Change     % Change    
Revenues   (Dollars in thousands)    
Afrezza     15,273       14,887       386       3 %  
Furoscix     15,493       —       15,493     N/A    
V-Go     3,141       4,086       (945 )     (23 %)  
Collaborations and services     23,515       29,376       (5,861 )     (20 %)  
Royalties     32,749       30,005       2,744       9 %  
Total revenues   $ 90,171     $ 78,354     $ 11,817       15 %  


Total revenues for the first quarter of 2026 increased compared to the same period in the prior year due to higher revenue from royalties and commercial product sales. Commercial product sales increased primarily due to net sales of Furoscix. The acquisition of scPharma closed on October 7, 2025. Collaborations and services revenue decreased due to fewer units sold to United Therapeutics (UT). The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights

Conference Call and Webcast
MannKind will host a conference call and webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours after the call and accessible for approximately 90 days.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding MannKind's expectations about 2026 being a catalyst-rich year; the potential benefits of and potential pediatric launch of Afrezza, and the expected timing thereof; expectations regarding MannKind’s ongoing and planned clinical trials and nonclinical studies, including the timing for enrollment for the Phase 2 clinical trial of MNKD-201 in IPF and the expected timing for data readouts from the Phase 1b clinical trial of MNKD-201, and preclinical development of MNKD-701 and MNKD-1501; development plans for MNKD-1501 and the potential achievement of milestone payments and royalties; the opportunity and potential benefits of Furoscix; the potential approval of Furoscix ReadyFlow Autoinjector, the timing of such approval and its potential impact on the growth trajectory for Furoscix; and the potential of MannKind to deliver long-term value. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential,” “prepare,” “opportunity” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; risks associated with competition; manufacturing risks; market adoption risks; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Tyvaso DPI is a trademark of United Therapeutics Corporation.

AFREZZA, FUROSCIX, MANNKIND, and V-GO are registered trademarks, and Furoscix ReadyFlow is a trademark of MannKind Corporation.


MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

    Three Months
Ended March 31, 		 
    2026     2025  
    (In thousands except per share data)  
Revenues:            
Commercial product sales   $ 33,907     $ 18,973  
Collaborations and services     23,515       29,376  
Royalties     32,749       30,005  
Total revenues     90,171       78,354  
Expenses:            
Cost of goods sold – commercial, excluding amortization of acquired intangible assets     7,509       3,768  
Cost of revenue – collaborations and services     9,964       13,748  
Research and development     17,231       11,022  
Selling, general and administrative     54,085       25,014  
Amortization of acquired intangible assets     4,367       —  
(Gain) loss on foreign currency transaction     (1,318 )     2,509  
Total expenses     91,838       56,061  
(Loss) income from operations     (1,667 )     22,293  
Other income (expense):            
Interest income, net     1,429       1,956  
Interest expense     (7,478 )     (4,645 )
Interest expense on liability for sale of future royalties     (2,563 )     (3,577 )
Interest expense on financing liability     (2,393 )     (2,410 )
Loss on settlement of debt     (917 )     —  
Other expense     (2,777 )     —  
Total other expense     (14,699 )     (8,676 )
(Loss) income before income tax expense     (16,366 )     13,617  
Income tax expense     253       459  
Net (loss) income   $ (16,619 )   $ 13,158  
Net (loss) income per share – basic   $ (0.05 )   $ 0.04  
Weighted average shares used to compute net (loss) income
per share – basic		     308,267       303,481  
Net (loss) income per share – diluted   $ (0.05 )   $ 0.04  
Weighted average shares used to compute net (loss) income
per share – diluted		     308,267       320,897  


             
MANNKIND CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS 		 
             
    March 31, 2026     December 31, 2025  
    (In thousands except share
and per share data) 		 
ASSETS            
Current assets:            
Cash and cash equivalents   $ 52,834     $ 74,882  
Short-term investments     81,027       96,464  
Accounts receivable, net     28,137       38,367  
Inventory     49,166       35,313  
Prepaid expenses and other current assets     39,996       46,553  
Total current assets     251,160       291,579  
Restricted cash     747       745  
Long-term investments     —       5,012  
Property and equipment, net     82,554       82,423  
Goodwill     67,595       67,595  
Developed technology - on-body infusor     185,708       190,027  
IPR&D - ReadyFlow Formulation     129,600       129,600  
Other intangible assets     5,024       5,072  
Other assets     22,015       20,129  
Total assets   $ 744,403     $ 792,182  
             
LIABILITIES AND STOCKHOLDERS' DEFICIT            
Current liabilities:            
Accounts payable   $ 16,144     $ 9,034  
Accrued expenses and other current liabilities     58,598       64,628  
Senior convertible notes – current     —       36,280  
Liability for sale of future royalties – current     14,010       14,298  
Contingent consideration - current     23,877       21,132  
Financing liability – current     10,407       10,328  
Deferred revenue – current     11,525       15,331  
Total current liabilities     134,561       171,031  
Liability for sale of future royalties – long term     136,561       136,985  
Financing liability – long term     92,784       93,092  
Deferred revenue – long term     38,905       39,977  
Recognized loss on purchase commitments – long term     64,635       65,952  
Operating lease liability     10,281       10,689  
Contingent consideration – long term     5,146       5,114  
Milestone liabilities     2,003       2,003  
Term loan     318,722       318,361  
Total liabilities     803,598       843,204  
Commitments and contingencies            
Stockholders' deficit:            
Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized;
no shares issued or outstanding as of March 31, 2026 or December 31, 2025		     —       —  
Common stock, $0.01 par value – 800,000,000 shares authorized;
308,907,331 and 307,832,587 shares issued and outstanding as of
March 31, 2026 and December 31, 2025, respectively		     3,089       3,078  
Additional paid-in capital     3,150,295       3,141,741  
Accumulated other comprehensive (loss) income     (4 )     115  
Accumulated deficit     (3,212,575 )     (3,195,956 )
Total stockholders' deficit     (59,195 )     (51,022 )
Total liabilities and stockholders' deficit   $ 744,403     $ 792,182  


Non-GAAP Measures

To supplement our condensed consolidated financial statements presented under GAAP, we are presenting non-GAAP net (loss) income and non-GAAP net (loss) income per share – basic, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future
cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non- GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following table reconciles our financial measures for net (loss) income and net (loss) income per share ("EPS") for basic weighted average shares as reported in our condensed consolidated statement of operations to a non-GAAP presentation:

    Three Months
Ended March 31, 		 
    2026     2025  
    Net Income     Basic EPS     Net Income     Basic EPS  
                         
GAAP reported net (loss) income   $ (16,619 )   $ (0.05 )   $ 13,158       0.04  
Non-GAAP adjustments:                        
Stock compensation     6,455       0.02       5,385       0.02  
Interest expense on liability for sale of future royalties     2,563       0.01       3,577       0.01  
Sold portion of royalty revenue(1)     (3,275 )     (0.01 )     (3,000 )     (0.01 )
(Gain) loss on foreign currency transaction     (1,318 )     0.00       2,509       0.01  
Amortization of intangible assets acquired     4,367       0.01       —       —  
Loss on settlement of debt     917       0.00       —       —  
Non-GAAP adjusted net (loss) income   $ (6,910 )   $ (0.02 )   $ 21,629     $ 0.07  
Weighted average shares used to compute net (loss) income per share – basic     308,267             303,481        


(1) Represents the non-cash portion of the 1% royalty on net sales of Tyvaso DPI earned during the three months ended March 31, 2026 and 2025 which is remitted to the royalty purchaser and recognized as royalties from collaborations in our condensed consolidated statements of operations. Our revenues from royalties from collaborations during the three months ended March 31, 2026 and 2025 totaled $32.7 million and $30.0 million, respectively, of which $3.3 million and $3.0 million, respectively, was remitted to the royalty purchaser. 



MannKind Contacts:
Investor Relations
Kate Miranda
Email: ir@mnkd.com

Media Relations
Christie Iacangelo
Email: media@mnkd.com

Primary Logo